Skip to Main Content
Pharmacy Technician's Letter
Menu
    • Products
      • Hospital Pharmacist's Letter
      • Hospital Pharmacy Technician's Letter
      • Learning Management Portal
      • Natural Medicines
      • Pharmacist's Letter
      • Pharmacist's Letter Canada
      • Pharmacy Technician's Letter
      • Pharmacy Technician's Letter Canada
      • Prescriber's Letter
      • RxAdvanced
      • RxSelect

    Subscribe Login
  • Home
  • Letter
    • Current Issue
    • Past Issues
    • Suggest a Topic
  • Browse
    • Subject
    • Charts
    • COVID-19 Resources
    • Diabetes Resources
    • Immunization Resources
    • Natural Medicines Resources
    • Opioid Resources
    • Transitions of Care Resources
  • CE & Training
    • CE Organizer
    • Available Courses
    • Live CE Calendar
    • Print Statements
    • Licenses
    • NABP
    • National Certification
    • Additional Requirements
    • Exemptions
  • Podcasts
  • New Drugs
    • New Drugs
    • First Time Generics
  • Help
    • User Support
    • Contact Us

Upgrade Your Browser

We no longer support this version of your browser. We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.

Return to the course you were viewing

New! PTU Elite: Controlled Substances & Diversion prepares pharmacy technicians to manage controlled substances, covering everything from best practices for filling prescriptions to recordkeeping. Learn More.
  1. Home
  2. Browse
  3. Hematology & Oncology
  4. Chemotherapy-Induced Adverse Effects
  5. Osteoporosis

Osteoporosis

  • Anemia (41)
  • Blood Products (4)
  • Breast Cancer (65)
  • Cancer (16)
  • Cervical Cancer (14)
  • Chemotherapy (4)
  • Chemotherapy-Induced Adverse Effects (34)
    • Dry Mouth (6)
    • Mucositis (11)
    • Nausea and Vomiting (18)
    • Osteoporosis (4)
  • Colon Cancer (13)
  • Drugs/Products That May Increase Cancer Risk (80)
  • Gastrointestinal Cancers (23)
  • Hemophilia (1)
  • Hemorrhage (5)
  • Leukemia (1)
  • Lung Cancer (74)
  • Lymphoma & Multiple Myeloma (1)
  • Ovarian Cancer (1)
  • Prostate Cancer (17)
  • Renal Cancer (1)
  • Resources (54)
  • Sickle Cell Disease (4)
  • Skin Cancer (20)
1 - 4 of 4 Results
Sort Results:
  • Title: Ascending (A-Z)
  • Date: Newest First
  • Date: Oldest First
Commentary: Bisphosphonates-Associated Jaw Osteonecrosis August 2006
Patient Education: Bisphosphonates and Jaw Bone Damage August 2006
Guideline: Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from theAmerican Dental Association Council on Scientific Affairs (2008) August 2006
Article: Boniva (ibandronate), the new once-MONTHLY bisphosphonate for osteoporosis May 2005
  • 1
  • About Us
  • Our Mission
  • Our Team
  • Careers
  • News and Resources
  • Products
  • Individual Solutions
  • Enterprise Solutions
© Therapeutic Research Center. All Rights Reserved